Downstream Processing Market Analysis

Downstream Processing Market Analysis

To get key market trends

  Download Free Sample

The purification segment accounted for 42.3% of the downstream processing market share in 2022. Purification is an essential step to remove impurities, contaminants, and unwanted byproducts which ensures the safety and efficacy of the bio-based product. It contributes to the consistency and reproducibility of the final product. It leads to higher yields of the targeted molecules by concentrating it while removing impurities which increases production efficiency and reduced production costs.
 

The solid-liquid separation segment is expected to grow at over 11.2% CAGR through 2032, due to its advantages such as enhanced product quality, reduced processing time, cost-effectiveness, simplicity, and are well suited for continuous manufacturing.
 

The chromatography columns and resins segment from downstream processing market will observe around 10.8% CAGR during the forecast period. Chromatography columns and resins can be designed with specific ligands or functional groups that selectively bind to the target molecule which leads to efficient separation and purification, even when the closely related molecules are present. They are essential in the production of high-quality biopharmaceuticals and biochemicals due to their effectiveness in efficiently purifying and separating target molecules. Furthermore, the increased research and development to improve the efficiency and speed of chromatography columns and resins are set to drive the growth.
 

The monoclonal antibody production segment held over 42.6% of the downstream processing market share in 2022 and is projected to reach USD 25.9 billion by 2032. Downstream processing plays a vital role in monoclonal antibody (mAb) production, offering several advantages that impacts the quality, efficiency, and success of the manufacturing process.
 

Monoclonal antibodies are widely used class of therapeutic proteins for treating different diseases including cancer, autoimmune disorders, and infectious diseases which is expected to drive the growth of this segment. The monoclonal antibodies are critical in nature and downstream processing ensures that these complex molecules are purified, concentrated, and formulated into safe and effective treatments.
 

The biopharmaceutical companies segment was over 60.3% of the downstream processing market share in 2022 and is anticipated to record a CAGR of 11.4% till 2032. With the increasing demand for biopharmaceuticals the number of such companies is globally increasing. These companies highly rely on downstream processing to meet the required quality, safety, and efficacy standards for the products they produce including proteins, antibodies, vaccines, and enzymes. It contributes to the economic viability of biopharmaceutical manufacturing by increasing the product yield and decreasing the cost of production.
 

North American downstream processing market size is estimated to cross USD 28.8 billion by 2032. North America has highly advance healthcare infrastructure with well-established pharmaceutical and biotechnology companies which increases the research, development, and production of pharmaceutical companies. In addition to this, presence of major biopharmaceutical companies, supportive regulatory agencies, strong research, and academic institutes, increasing demand for biopharmaceuticals and increasing clinical trials and drug development are the factors influencing the market growth.